Branch Retinal Vein Occlusions as a Serious Complication of Covid 19 Infection

Sanaa Ahmed Mohamed, Marwa Byomy, Eman El Sayed Mohamed El Sayed, Mostafa Osman Hussein, Marwa M. Abdulrehim, Ahmed Gomaa Elmahdy

1Department of Ophthalmology, Alazhar University, Cairo, Egypt; 2Department of Clinical Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt; 3Department of Ophthalmology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt; 4Department of Internal Medicine, Al-Azhar University (Girls), Cairo, Egypt

Abstract

BACKGROUND: Branch retinal vein occlusion (BRVO) has an incidence of 0.5–1.2%. COVID-19 is associated with both venous and arterial thromboembolisms due to excessive inflammation, hypoxia, immobilization, and diffuse intravascular coagulation.

AIM: The present study aims to describe our experience with BRVO in Egyptian COVID-19 patients.

PATIENTS AND METHODS: The present retrospective study included 17 polymerase chain reaction (PCR)-proven COVID-19 patients with BRVO. Data obtained from the studied patients included detailed history taking. In addition, patients were diagnosed with BRVO based on a comprehensive opthalmic evaluation, including logMAR Best-corrected visual acuity assessment, slit-lamp bio-microscopy, fundoscopy, fundus fluorescein angiography, and optical coherence tomography macular assessment.

RESULTS: The present study included 17 PCR-proven COVID-19 patients with BRVO. They comprised 9 males (52.9%) and 8 females (47.1%) with an age of 52.8 ± 13.3 years. Fundus examination revealed BRVO as superior temporal in 9 patients (52.9%), inferior temporal in 5 patients (29.4%), superior nasal in 2 patients (11.8%), and inferior nasal in 1 patient (5.9%). The reported retinal thickness was 355.7 ± 41.7 μm. In addition, fundus fluorescein angiography identified ischemic changes in 2 patients (11.8%).

CONCLUSION: BRVO is a rare severe complication of COVID-19 infection. In patients with proven or suspected infection with a diminution of vision, there should be high suspicion of BRVO and prompt full-scale ophthalmological examination to exclude the condition.

Introduction

Retinal vein occlusion (RVO) is the second most common retinal vascular disorder after diabetic retinopathy. Branch RVO (BRVO) has an incidence of 0.5–1.2% [1]. BRVOs have two major forms, non-ischemic and ischemic, which are detected in one-third and two-thirds of cases, respectively [2]. Typically, patients present with sudden painless vision loss or visual field defect [3]. Funduscopic examination may reveal flame hemorrhages, dot and blot hemorrhages, cotton wool spots, hard exudates, retinal edema, and dilated tortuous veins [4]. Characteristic findings of BRVO on optical coherence tomography (OCT) include cystoid macular edema, intraretinal hyper-reflectivity from hemorrhages, shadowing from edema and hemorrhages, and occasionally subretinal fluid [5], [6].

The pathogenesis of BRVO is multifactorial, including a combination of mechanical compression, degenerative changes in vessel walls, and/or hypercoagulable factors [7]. Macular edema is the main cause of vision loss in BRVO. The pathogenesis of macular edema is believed to be a result of multiple inflammatory cascades. Analysis of vitreous samples from patients with BRVO has established an association with increased levels of VEGF, IL-6, IL-8, and monocyte chemoattractant protein-1 compared to controls [8], [9].

COVID-19 is associated with both venous and arterial thromboembolisms due to excessive inflammation, hypoxia, immobilization, and diffuse intravascular coagulation [10], [11]. The prevalence of venous thromboembolic events has been found to be as high as 27% [12], [13]. In addition, microangiopathic retinal changes have been observed in COVID-19 patients [14]. However, it’s not clear whether these changes are due to prolonged hypoxemia or direct viral etiology [15], [16].

In fact, the SARS-CoV-2 virus had been detected in many diverse ocular specimens, including in the tears and conjunctival secretions of patients with coronavirus conjunctivitis [17], [18]. Furthermore, SARS-CoV-2 has been identified in retina samples of deceased patients with confirmed COVID-19 disease [19]. Interestingly,
The present study describes our experience with BRVO in Egyptian COVID-19 patients.

Patients and Methods

The present retrospective study was conducted at Al-Azhar University Hospitals, Cairo, Egypt. Approval from the Ethics Committee was obtained. Written informed consent was taken from all patients for participation in the study after explaining the purpose of the study based on the Helsinki Declaration of clinical studies, including human subjects.

The study included 17 polymerase chain reaction (PCR)-proven COVID-19 patients with BRVO. Data obtained from the studied patients included detailed history taking. For laboratory assessment, two blood samples were obtained from all patients, including 2 ml of blood on an EDTA tube for assessment of CBC and 5 ml of blood in a serum tube for serum assessment of C-reactive protein, ferritin, lactic dehydrogenase (LDH), and D-dimer and performing anti-COVID IgM/IgG Antibody Test (Artron Laboratories, Canada).

Based on the comprehensive ophthalmic evaluation, patients were diagnosed with BRVO, including logMAR best-corrected visual acuity (BCVA) assessment, slit-lamp bio-microscopy, fundoscopy, fundus fluorescein angiography, and OCT macular assessment.

Patients with macular edema were treated using monthly intravitreal injections of ranibizumab (0.5 mg/0.05 ml) for 3 months. Patients were subjected to a full ophthalmic examination 1 week after every injection. In addition, OCT was done 1 month after the last injection, together with an assessment of logMAR BCVA. Data obtained from the present study were presented as number and percent or mean and standard deviation.

Results

The present study included 17 PCR-proven COVID-19 patients with BRVO. They comprised 9 males (52.9%) and 8 females (47.1%) with an age of 52.8 ± 13.3 years. Clinical and laboratory findings in the studied patients are shown in Table 1. Fundus examination revealed BRVO as superior temporal in 9 patients (52.9%), inferior temporal in 5 patients (29.4%), superior nasal in 2 patients (11.8%), and inferior nasal in 1 patient (5.9%). The reported retinal thickness was 355.7 ± 41.7 µm. Fundus fluorescein angiography identified ischemic changes in 2 patients (11.8%) (Table 2). The OCT retinal thickness had a clear, strong positive correlation that was highly significant with site BRAVO, FFA, Intraocular pressure, BCVA, lymphocytes, Hb, D-dimer, and total leucocytic count (TLC). Furthermore, the OCT retinal thickness significantly negatively correlated with the cataract, neutrophils, PLT, and LDH (Figure 1).

Table 1: Clinical and laboratory findings in the studied patients (n=17)

| Parameters       | Value         |
|------------------|---------------|
| Age (years)      | 52.8 ± 13.3   |
| Male/female, n   | 9/7           |
| Diabetes mellitus, n (%) | 7 (41.2) |
| Hypertension, n (%) | 5 (29.4) |
| Anti-coagulants, n (%) | 4 (23.5) |
| CRP (mg/L)       | 5.2 ± 0.4     |
| LDH (IU/L)       | 262.3 ± 42.1  |
| D-Dimer (μM/L)   | 0.55 ± 0.12   |
| TLC (×10³/mℓ)    | 7.2 ± 2.6     |
| Lymphocytes (%)  | 32.2 ± 11.3   |
| Neutrophils (%)  | 65.7 ± 12.2   |
| Anti-coagulants |               |
| CRP, LDH, D-dimer, TLC, Total leucocytic count |

Table 2: Ophthalmic findings in the studied patients (n=17)

| Parameters       | Value         |
|------------------|---------------|
| BCVA, mean ± SD  | 0.36 ± 0.14   |
| IOP (mmHg), mean ± SD | 15.94 ± 3.05 |
| Cataract, n (%)  | 2 (11.8)      |
| Site of BRVO, n (%) | 9 (52.9) |
| Superior temporal| 5 (29.4)      |
| Inferior temporal|              |
| Superior nasal   | 2 (11.8)      |
| Inferior nasal   | 1 (5.9)       |
| Retinal thickness (µm), mean ± SD | 355.7 ± 41.7 |
| Fundus fluorescein angiography, n (%) | 2 (11.8) |
| Ischemic         |               |
| Nonischemic      | 15 (88.2)     |
| BCVA: Best-corrected visual acuity, IOP: Intraocular pressure, SD: Standard deviation |

Discussion

Hypercoagulability and hyperinflammatory response are major contributors to morbidity and mortality in patients with COVID-19 [22], [23]. The reported clinical spectrum included deep venous thromboses, pulmonary emboli, and ischemic strokes resulting from COVID-19 [24]. Many ocular manifestations have been reported in association with COVID-19, the most common being conjunctivitis seen in 0.8% of patients [25].

In this retrospective study, we documented the largest series of BRVO related to COVID-19 infection to the best of our knowledge. Unfortunately, most published data on this issue involve single-patient case reports. In addition, our study included only BRVO patients with PCR-proven COVID-19 infection.

Sheth et al. [26] reported a case of vasculitic RVO secondary to COVID-19 in a 52-year-old patient who presented with a diminution of vision in the left eye 10 days after he tested positive for SARS-CoV-2. Furthermore, Venkatesh [15] reported a case of a
56-year-old female with CRVO. She tested positive for SARS-CoV-2 IgG and negative for IgM, denoting old COVID-19 infection. In another work, Walinjkar [27] reported a case of a 66-year-old male with combined CRAO and CRVO with proven COVID-19 infection, diagnosed after the presentation. Moreover, Duff et al. [28] reported a 74-year-old female patient who initially presented with blurry vision in her left eye in the setting of symptomatic COVID-19 infection. She was diagnosed with a BRVO.

The current investigation was subject to a number of limitations. First, the small number of patients who were investigated was one limitation. Future research should include larger sample size, be broken up into more specific phases, and be categorized by severity. Nevertheless, since there were only 17 eyes included in the research, we could not incorporate a variety of BRVO eyes. Second, every test strategy should examine several retinal regions. Therefore, our deficient data analyses should be explained by conducting more extensive, prospective research.

Conclusion

BRVO is a rare serious complication of COVID-19 infection. The exact pathogenic factors involved remain to be elucidated. In patients with proven or suspected infection with a diminution of vision, there should be high suspicion of BRVO and prompt full-scale ophthalmological examination to exclude the condition.

Acknowledgments

The authors of the present study would like to thank all participants of the study.

Declarations

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Ethics approval

The study followed the instructions of Al Azhar Medical research Ethical, Cairo, Egypt, with reference No. 0000053. All authors have read and agreed to the published version of the manuscript.

References

1. Jaulim A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion: Epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina. 2013;33(5):991-10. https://doi.org/10.1097/ IAE.0b013e3182870c15
PMid:23609064
2. Lin LL, Dong YM, Zong Y, Zheng QS, Fu Y, Yuan YG, et al.
Study of retinal vessel oxygen saturation in ischemic and non-ischemic branch retinal vein occlusion. Int J Ophthalmol. 2016;9(1):99-107. https://doi.org/10.18240/ijo.2016.01.17

PMid:2694961

3. Tripathy K, Sharma YR, Chawla R, Basu K, Vohra R, Venkatesh P. Triads in ophthalmology: A comprehensive review. Semin Ophthalmol. 2017;32(2):237-50. https://doi.org/10.3109/08820538.2015.1045150

PMid:26148300

4. Kimmel AS, Magargal LE, Morrison DL, Robb-Doyle E. Temporal branch retinal vein obstruction masquerading as a retinal arterial macroaneurysm. The Bonet sign. Ann Ophthalmol. 1989;21(7):251-2.

PMid:2774431

5. Kumagai K, Tsujikawa A, Muraoka Y, Akagi-Kurashige Y, Murakami T, Miyamoto K, et al. Three-dimensional optical coherence tomography evaluation of vascular changes at arteriovenous crossings. Invest Ophthalmol Vis Sci. 2014;55(3):1867-75. https://doi.org/10.1167/iovs.13-13303

PMid:24576872

6. Ota M, Tsujikawa A, Murakami T, Kita M, Miyamoto K, Sakamoto A, et al. Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. Br J Ophthalmol. 2007;91(12):1644-9. https://doi.org/10.1136/bjo.2007.118497

PMid:17504858

7. Frenkli SA, Mozaffarieh M, Flammer J. Retinal vein occlusions: The potential impact of a dysregulation of the retinal veins. EPMA J. 2010;1(2):253-61. https://doi.org/10.1007/s13167-010-0025-2

PMid:21258633

8. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Oshima Y, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009;4(12):e8158. https://doi.org/10.1371/journal.pone.0008158

PMid:19907642

9. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834-47. https://doi.org/10.1002/ajh.25829

PMid:32282949

10. Ferrara M, Romano V, Steel DH, Gupta R, Iovino C, van Dijk EH, et al. Reshaping ophthalmology training after COVID-19 pandemic. Eye (Lond). 2020;34(11):2089-97. https://doi.org/10.1038/s41433-020-1061-3

PMid:32612174

11. Klok FA, Kruip M, van der Meer NJ, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-7. https://doi.org/10.1016/j.thromres.2020.04.013

PMid:32291094

12. Bonzano C, Borroni D, Lancia A, Bonzano E. Doxycycline: From oral rosacea to COVID-19 anosmia. New insight into the coronavirus outbreak. Front Med. 2020;7:200. https://doi.org/10.3389/fmed.2020.00200

PMid:32574320

13. Marinho PM, Marcos AA, Romano AC, Nascimento H, Belfort R Jr. Retinal findings in patients with COVID-19. Lancet. 2020;395(10237):1610. https://doi.org/10.1016/S0140-6736(20)31014-X

PMid:32405105

14. Venkatesh P. Seeking clarity on retinal findings in patients with COVID-19. Lancet. 2020;396(10254):e36.

15. El-Sheshtawy HS, Sofy MR, Ghareeb DA, Yacout GA, Eldemellawy MA, Ibrahim BM. Eco-friendly polyurethane acrylate (PUA)/natural filler-based composite as an antifouling product for marine coating. Appl Microbiol Biotechnol. 2021;105(18):7023-34. https://doi.org/10.1007/s00253-021-11501-w

PMid:34103402

16. Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 2020;92(6):589-94. https://doi.org/10.1002/jmv.25725

PMid:32100876

17. Agha MS, Abbas MA, Sofy MR, Haroun SA, Mowafy AM. Dual inoculation of Bradyrhizobium and Enterobacter alleviates the adverse effect of salinity on Glycine max seedling. Not Bot Horti Agrobot Cluj Napoca. 2021;49(3):12461. https://doi.org/10.15835/nbha49312461

PMid:32469258

18. Senanayake PD, Bonilha VL, Peterson JW, Yamada Y, Karnik SS, Daneshgari F, et al. Retinal angiotensin II and angiotensin-(1-7) response to hyperglycemia and an intervention with captopril. J Renin Angiotensin Aldosterone Syst. 2018;19(3). https://doi.org/10.1177/147032031879323

PMid:30126320

19. Sofy MR, Mancy AG, Alnaggar AE, Refaey EE, Mohamed HI, Elnosey ME, et al. A polishing the harmful effects of Broad bean mottle virus infecting broad bean plants by enhancing the immunity using different potassium concentrations. Not Bot Horti Agrobot Cluj Napoca. 2020;50(1):12461. https://doi.org/10.15835/nbha49312461

PMid:32469258

20. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboembolastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738-42. https://doi.org/10.1111/jth.14850

PMid:32302438

21. Rotzinger DC, Beigelman-Aubry C, von Garnier C, Qanadli SD. Pulmonary embolism in patients with COVID-19: Time to change the paradigm of computed tomography. Thromb Res. 2020;190:58-9. https://doi.org/10.1016/j.thromres.2020.04.011

PMid:32302782

22. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7. https://doi.org/10.1111/jth.14768

PMid:32073213

23. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. https://doi.org/10.1056/NEJMo2002032

24. Sheth JU, Narayanani R, Goyal J, Goyal V. Retinal vein occlusion in COVID-19: A novel entity. Indian J Ophthalmol. 2020;68(10):2291-3. https://doi.org/10.4103/ijo.IJO_2380_20

PMid:32971697

25. Walinjkar JA. Combined retinal vascular occlusion in a recovered case of COVID-19. Apollo Med. 2021;18(3):205-7. https://doi.org/10.4103/am.am_38_21

PMid:33815989